Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2015

01-12-2015 | Original Article

Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer

Authors: Tatsuya Kurihara, Mari Kogo, Masakazu Ishii, Ken Shimada, Keiichiro Yoneyama, Katsuya Kitamura, Shunichi Shimizu, Hitoshi Yoshida, Yuji Kiuchi

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2015

Login to get access

Abstract

Purpose

We conducted a retrospective cohort study to examine whether neutropenia could be an indicator of good prognosis in patients treated with gemcitabine (GEM) for unresectable pancreatic cancer.

Methods

A total of 178 patients with unresectable pancreatic cancer, who were treated with first-line (n = 121) or second-line (n = 57) GEM, were included in our analyses. A Cox proportional hazard model was used to examine the effect of the grade of GEM-induced neutropenia on prognosis. Furthermore, the difference in survival time for each grade was assessed using a log-rank test.

Results

In the first-line population, the hazard ratios of patients with grade 2 or grade 3 neutropenia compared with the ratios of those without neutropenia (grade 0) were 0.43 (95% CI 0.27–0.70) and 0.37 (0.21–0.65), respectively (p < 0.05). The median survival time (MST) was 3.8 months for grade 0, 9.4 months for grade 2, and 10.1 for grade 3. Landmark analysis of the second-line population revealed a hazard ratio of 0.52 (0.30–0.82) for grade 1 and 0.49 for grade 2 (0.28–0.72) (p < 0.05). MST was 1.3 months for grade 0, 4.7 months for grade 1, and 4.6 months for grade 2.

Conclusions

We found that neutropenia grade was an indicator of good prognosis in patients treated with first-line and second-line GEM for unresectable pancreatic cancer. A prospective study should be performed to examine whether dosage adjustment using neutropenia grade as an indicator would improve prognosis.
Literature
1.
2.
3.
Bramhall SR, Rosemurgy A, Brown PD et al (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19:3447–3455PubMed
4.
Heinemann V, Quietzsch D, Gieseler F et al (2006) A phase III trial comparing gemcitabine plus cisplatine compared with gemcitabine alone in advanced pancreatic adenocarcinoma. J Clin Oncol 24:3946–3952CrossRefPubMed
5.
Van Cutsem E, van de Velde H, Karasek P et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438CrossRefPubMed
6.
Oettle H, Richards D, Ramanathan RK et al (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 10:1639–1645CrossRef
7.
Louvet C, Labianca R, Hammel G et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Cin Oncol 23:3509–3516CrossRef
8.
Reni M, Cordio S, Milandri C et al (2005) Gemcitabine versus cisplatin, epirubicin, fluorouracil and gemcitabine in advanced pancreatic cancer: a randomised controlled multicenter phase III trial. Lancet Oncol 6:369–376CrossRefPubMed
9.
Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966CrossRefPubMed
10.
Cunningham D, Chau I, Stocken DD et al (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513–5518CrossRefPubMed
11.
Rocha Lima CMS, Green MR, Rotche R et al (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776–3783CrossRefPubMed
12.
Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825CrossRefPubMed
13.
Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703CrossRef
14.
Yamaguchi K, Okusaka T, Shimizu K et al (2014) EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. Jpn J Clin Oncol 44:883–888CrossRefPubMed
15.
Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75:301–305PubMedCentralCrossRefPubMed
16.
Cameron DA, Massie C, Kerr G, Leonard RC (2003) Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89:1837–1842PubMedCentralCrossRefPubMed
17.
Di Maio M, Gridelli C, Gallo C et al (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6:669–677CrossRefPubMed
18.
Pallis AG, Agelaki S, Kakolyris S et al (2008) Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. Lung Cancer 62:356–363CrossRefPubMed
19.
Carus A, Gurney H, Gebski V et al (2013) Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med 11:189PubMedCentralCrossRefPubMed
20.
Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M (2007) Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer 97:37–42PubMedCentralCrossRefPubMed
21.
Shitara K, Matsuo K, Takahari D et al (2009) Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer 45:1757–1763CrossRefPubMed
22.
Sunaga T, Suzuki S, Kogo M et al (2014) The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy. Eur J Cancer Care (Engl) 23:394–400CrossRef
23.
Rocconi RP, Matthews KS, Kemper MK et al (2008) Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients. Gynecol Oncol 108:336–341CrossRefPubMed
24.
25.
Ueno H, Okada S, Okusaka T et al (2000) Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 59:296–301CrossRefPubMed
26.
Louvet C, Labianca R, Hammel G et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Cin Oncol 23:3509–3516CrossRef
27.
Maréchal R, Demols A, Gay F et al (2007) Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer. Oncology 73:41–51CrossRefPubMed
28.
Sawaki A, Kanemitsu Y, Mizuno N et al (2008) Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine. J Gastroenterol Hepatol 23:1292–1297CrossRefPubMed
29.
Tanaka T, Ikeda M, Okusaka T et al (2008) Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol 38:755–761CrossRefPubMed
30.
Kurihara T, Kogo M, Ishii M et al (2015) Practical Prognostic Index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1. Hepatogastroenterology 62:478–484PubMed
31.
Yoneyama K, Katsumoto E, Kurihara T et al (2012) Factors predicting the appearance of neutropenia in patients with advanced pancreatic cancer undergoing gemcitabine therapy. Hepatogastroenterology 59:894–898PubMed
32.
Frei E 3rd, Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69:585–594CrossRefPubMed
33.
34.
35.
36.
Helmut S, Oka M, Thomas B et al (2003) Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 103:335–343CrossRef
37.
Peter S, Jess DS, Ben JZP et al (2001) Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 189:197–206CrossRef
38.
Ren G, Zhao X, Wang Y et al (2012) CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell 11:812–824PubMedCentralCrossRefPubMed
Metadata
Title
Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer
Authors
Tatsuya Kurihara
Mari Kogo
Masakazu Ishii
Ken Shimada
Keiichiro Yoneyama
Katsuya Kitamura
Shunichi Shimizu
Hitoshi Yoshida
Yuji Kiuchi
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-015-2887-4

Other articles of this Issue 6/2015

Cancer Chemotherapy and Pharmacology 6/2015 Go to the issue

Original Article

Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells

Original Article

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

Letter to the Editor

Erlotinib-related rhabdomyolysis: the role of pharmacogenetics and drug–drug interaction

Review Article

Targeted therapy in cancer

Original Article

The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment

Original Article

Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits